Updated safety and efficacy data of combined KRAS G12C inhibitor (glecirasib, JAB-21822) and SHP2 inhibitor (JAB-3312) in patients with KRAS p.G12C mutated solid tumors.,Journal of Clinical Oncology

当前位置： X-MOL 学术 › J. Clin. Oncol. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Updated safety and efficacy data of combined KRAS G12C inhibitor (glecirasib, JAB-21822) and SHP2 inhibitor (JAB-3312) in patients with KRAS p.G12C mutated solid tumors.
Journal of Clinical Oncology ( IF 42.1 ) Pub Date : 2024-05-29 , DOI: 10.1200/jco.2024.42.16_suppl.3008
Jun Zhao ₁ , Jian Fang ₂ , Yan Yu ₃ , Qian Chu ₄ , Xiaoyan Li ₅ , Jiayan Chen ₆ , Zhe Liu ₇ , Li Zhang ₈ , Lin Wu ₉ , Wu Zhuang ₁₀ , XingYa Li ₁₁ , Yanqiu Zhao ₁₂ , Ligang Xing ₁₃ , Lian Liu ₁₄ , Chunmei Bai ₁₅ , Xiaorong Dong ₁₆ , Qibin Song ₁₇ , Pinghua Pan ₁₈ , Xuefeng Fang ₁₉ , Jie Wang ₂₀

Affiliation

Key laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department I of Thoracic Oncology, Peking University Cancer Hospital and Institute, Beijing, China
Second Department of Thoracic Tumors, Peking University Cancer Hospital, Beijing, China
Department of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China
Tongji Hospital, Tongji Medical College Huazhong University of Science and Technology, Wuhan, China
Beijing Tian Tan Hospital, Capital Medical University, Beijing, Fengtai District, China
Fudan University Shanghai Cancer Center, Shanghai, China
Department of Medical Oncology, Beijing Chest Hospital, Capital Medical University, Beijing, China
Department of Respiratory and Critical Care Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
Thoracic Internal Medicine Oncology Department, Hunan Cancer Hospital, Changsha, Hunan, China
Department of Thoracic Oncology, Fujian Medical University, Fujian Cancer Hospital, Fuzhou, China
Department of Medical Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
Henan Cancer Hospital, Zhengzhou, China
Shandong Cancer Hospital, Jinan, China
Department of Medical Oncology, Qilu Hospital of Shandong University, Jinan, China
Department of medical onclogy, Peking Union Medical College Hospital, Beijing, China
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
Renmin Hospital of Wuhan University, Wuhan, China
Xiangya Hospital Central South University, Changsha, China
Department of Medical Oncology, Key Laboratory of Cancer Prevention and Intervention, Ministry of Education, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

Journal of Clinical Oncology, Volume 42, Issue 16_suppl, Page 3008-3008, June 2024.

中文翻译：

更新了 KRAS G12C 抑制剂（glecirasib、JAB-21822）和 SHP2 抑制剂（JAB-3312）联合治疗 KRAS p.G12C 突变实体瘤患者的安全性和有效性数据。

《临床肿瘤学杂志》，第 42 卷，第 16 期_suppl，第 3008-3008 页，2024 年 6 月。

更新日期：2024-05-30

点击分享查看原文

点击收藏

阅读更多本刊新发论文本刊介绍/投稿指南